This study shows that 3x a week interferon-beta therapy (e.g., Rebif) is superior to 1x a week (e.g., Avonex) -- an important finding for those choosing between therapies.
"IFN-beta therapy has a central place in the management of relapsing multiple sclerosis, as demonstrated by the pivotal studies of three IFN-beta treatment regimens. However, questions remain concerning the optimal choice of preparation and dose regimen...
The added benefit of high-dose, high-frequency IFN-beta therapy is not achieved at the cost of compromised safety or tolerability, indicating that three-times-weekly treatment offers a superior benefit-risk ratio to once-weekly treatment."
Click "read more" for the full abstract...
Advertisement
Full Abstract Text
Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis.
Francis G.
Elan Pharmaceuticals, 182 King Caesar Road, Duxbury, MA 02332, USA. gordon.francis@elan.com
IFN-beta therapy has a central place in the management of relapsing multiple sclerosis, as demonstrated by the pivotal studies of three IFN-beta treatment regimens. However, questions remain concerning the optimal choice of preparation and dose regimen. The benefit-risk ratio for a given preparation is an important consideration in optimising treatment for an individual patient. Of the three IFN-beta preparations currently available, all have shown benefit on activity measures (relapses and active lesions apparent on magnetic resonance imaging), while benefit on progression measures (disability and total lesion burden) has been less consistent. Available data across studies suggest that dose and/or dose frequency are important determinants of efficacy, a finding supported by direct comparative data on different IFN-beta preparations. The added benefit of high-dose, high-frequency IFN-beta therapy is not achieved at the cost of compromised safety or tolerability, indicating that three-times-weekly treatment offers a superior benefit-risk ratio to once-weekly treatment. The potential advantages of IFN-beta therapy may be enhanced by regular monitoring of efficacy and safety in order to maintain patients on therapy beyond the first few months when side effects are most apparent.
PMID: 15268647 [PubMed - in process]
Expert Opin Drug Saf. 2004 Jul;3(4):289-303.
Note: Note that while this study notes an Elan e-mail address, it was not sponsored by them but rather Serono, makers of Rebif.
